A new class of diabetes drugs, tipped to rake in billions of dollars, faces an uncertain future following six cases of severe pancreas inflammation linked to Amylin and Eli Lilly’s Byetta. So-called GLP-1 drugs like Byetta — and similar products being developed by firms including Novo Nordisk and Roche — are seen as a promising new way to fight the growing problem of diabetes, which is closely linked to obesity.
This is the first I have heard of these concerns. Byetta is a drug used to treat type 2 diabetes and is also known to help persons shed a lot …read more